Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
Article in English | WPRIM | ID: wpr-161406


Inflammation is a part of the complex biological responses of a tissue to injury that protect the organ by removing injurious stimuli and initiating the healing process, and is considered as a mechanism of innate immunity. To identify biologically active compounds against pathogenic inflammatory and immune responses, we fractionated water, aqueous methanol and n-hexane layers from nine kinds of leguminosae and examined anti-inflammatory activity of the fractions in human keratinocytes and mouse skin. Among the fractions, rf3 and rf4, isolated from the aqueous methanol layer of Astragalus sinicus L., exhibited the strongest reactive oxygen species (ROS)-scavenging and anti-inflammatory activities as measured by inhibition of the intracellular ROS production, nuclear factor-kappaB (NF-kappaB), janus kinase (JAK)/signal transducer and activator of transcription (STAT), and phosphatidylinositol 3-kinase/Akt signaling in cytokine-stimulated human keratinocytes, as well as by effects on T-cell differentiation in mouse CD4+ T cells. In addition, topical application of rf3 and rf4 suppressed the progression of psoriasis-like dermatitis and expression of pro-inflammatory mediators in interleukin (IL)-23-injected mouse ears. Our results suggest that Astragalus sinicus L. may ameliorate chronic inflammatory skin diseases due to its antioxidant and anti-inflammatory activities via regulation of the intracellular ROS production, NF-kappaB, JAK/STAT and PI3/Akt signaling cascades as well as immune responses, and these results are the first report that Astragalus sinicus L. exhibits pharmacological activity.

Animals , Anti-Inflammatory Agents/isolation & purification , Astragalus Plant/chemistry , Cell Line , Dermatitis/drug therapy , Humans , Interleukin-23/pharmacology , Janus Kinases/metabolism , Keratinocytes/drug effects , Mice , Mice, Inbred C57BL , NF-kappa B/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Plant Extracts/isolation & purification , Proto-Oncogene Proteins c-akt/metabolism , Reactive Oxygen Species/metabolism , STAT Transcription Factors/metabolism , Skin/drug effects
J. appl. oral sci ; 20(2): 128-138, Mar.-Apr. 2012. ilus, tab
Article in English | LILACS | ID: lil-626410


Recently, new treatment approaches have been developed to target the host component of periodontal disease. This review aims at providing updated information on host-modulating therapies, focusing on treatment strategies for inhibiting signal transduction pathways involved in inflammation. Pharmacological inhibitors of MAPK, NFκB and JAK/STAT pathways are being developed to manage rheumatoid arthritis, periodontal disease and other inflammatory diseases. Through these agents, inflammatory mediators can be inhibited at cell signaling level, interfering on transcription factors activation and inflammatory gene expression. Although these drugs offer great potential to modulate host response, their main limitations are lack of specificity and developments of side effects. After overcoming these limitations, adjunctive host modulating drugs will provide new therapeutic strategies for periodontal treatment.

Humans , Inflammation Mediators/antagonists & inhibitors , Intracellular Signaling Peptides and Proteins/therapeutic use , Molecular Targeted Therapy/methods , Periodontal Diseases/therapy , Signal Transduction/drug effects , Biofilms , Inflammation Mediators/immunology , Inflammation Mediators/metabolism , Intracellular Signaling Peptides and Proteins/immunology , Janus Kinases/immunology , Janus Kinases/metabolism , Mitogen-Activated Protein Kinases/immunology , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/immunology , NF-kappa B/metabolism , Periodontal Diseases/etiology , Periodontal Diseases/immunology , STAT Transcription Factors/immunology , STAT Transcription Factors/metabolism